论文部分内容阅读
目的:探讨葡萄籽原花青素(oligomeric proanthocyanidins,OPC)辅助治疗哮喘的临床价值.方法:60例以布地奈德福莫特罗吸入剂作为常规治疗的非急性发作期哮喘患者,随机分为安慰剂组及OPC高、中、低剂量干预组,药物干预持续8周;分别于受试前、干预第4周末、第8周末行哮喘控制测试(asthma control test,ACT)、外周血嗜酸性粒细胞(eosinophils,EOS)计数及肺功能检测.结果:OPC干预4周后,仅高剂量组外周血EOS数量显著下降(P＜0.05);持续干预至8周后,高剂量组ACT评分显著升高(P＜0.05),中、高剂量组外周血EOS数量显著下降(P＜0.05),中、高剂量组第1秒用力呼气容积占预计值百分比(FEV1％)显著升高、组间差异显著(P＜0.05).剂量及干预时间两个因素分别与ACT评分及FEV1％呈正相关(P＜0.05),与外周血EOS数量呈负相关(P＜0.05).结论:OPC可有效抑制气道炎症、改善通气功能、提高哮喘患者的生活质量,是极具潜力的哮喘辅助治疗候选药物.“,”Objective:This study investigated the impacts of oligomeric proanthocyanidins (OPC) on patient with asthma to develop new therapeutic options for asthma treatment.Methods:A total of 60 non-acute attack patients with asthma who conventionally received budesonide/formoterol inhalation were randomly divided into the placebo,high-,intermediate-and low-dosage OPC groups.The duration of OPC treatment ranged 8 weeks.Asthma control test(ACT) score,eosinophils(EOS) count and pulmonary function were analyzed.Results:A significant decrease of EOS in peripheral blood was observed in the high-dosage group who received OPC treatment after 4 weeks(P＜0.05).When the treatment expended up to 8 weeks,an elevated ACT score (P＜0.05) and forced expiratory volume in one second to forced vital capacity ratio (FEV1％) as well as a declined EOS count (P＜0.05) were found in the high-dosage group,while intermediate-dosage OPC only presented improvements in EOS count and FEV1％ (P＜0.05).Dosage and intervention duration were positively correlated with ACT score and FEV1％ (P＜0.05),and negatively correlated with the number of peripheral blood EOS (P＜0.05).Conclusion:Our results exhibited a novel profile of OPC as a potent option for airway inflammation relief and ventilation rescue,highlighting a promising role of OPC in asthma management.